Cerebellar Single Metastases from Bladder Transitional Cell Carcinoma: A Case Report

Metástase cerebelar única secundária a câncer de celulas transicionais de bexiga: relato de caso

Paulo Valdeci Worm1,2,4 Guilherme Finger2 Renan Desimon Cabral3 Jorge Luiz Kraemer4

1 Graduate Program in Medicine: Surgical Sciences. Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
2 Neurosurgery Department, Cristo Redentor Hospital, Porto Alegre RS, Brazil
3 Urology Department, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
4 Department of Neurological Surgery, São Jose Hospital, Santa Casa Hospital Complex, Porto Alegre, RS, Brazil


Address for correspondence Guilherme Finger, MD, Department of Neurosurgery, Hospital Cristo Redentor, Porto Alegre, Rio Grande do Sul, Brazil (e-mail: guilhermefingermd@gmail.com).

Abstract
Cerebral metastasis is the most common cancer in the Central Nervous System (CNS); however, the bladder is a rare primary origin. The incidence of bladder metastases to the brain tissue has slightly increased in the past decades, with a few case reports published in medical literature, but not in Brazil. The authors describe a case of a female with prior diagnosis and treatment of transitional cellular cancer, without signs or symptoms of local or disseminated relapse, who suddenly developed clinical signs of cerebellum impairment. The patient was submitted to neurosurgical procedure with good outcome, followed by oncologic adjuvant treatment.

Keywords
► urothelial carcinoma
► cerebral metastases
► transitional cell carcinoma

Introduction
Transitional cell carcinoma (TCC) constitutes the most common bladder tumor, usually diagnosed as a superficial lesion localized in the urothelial layer without systemic spread. However, metastases are frequent in detrusor-invasive cancer, occurring in 50% of patients.1,2 Among the possible sites of metastases, CNS is one of the least frequent tissue, and only occurs as a late event in the natural history of the disease. Cerebral evolvement is even
rarer in patients with systemic controlled disease, without signs of relapse in lungs or liver, for example.

This is a case report of a patient with previous diagnosis and treatment of TCC who developed a single cerebellar metastasis, without involvement of other organs, and was submitted to surgical resection with good outcome and forwarded to oncologic adjuvant treatment, with a good survival follow-up.

Case Report

A 72-year-old Caucasian woman, with a medical history of bladder carcinoma treated surgically two years earlier and without signs of local tumor relapse, according to periodic cystoscopy during follow-up, suddenly started with intermittent headache and dizziness. The patient had been complaining about these symptoms for two months, and denied previous head trauma or drug abuse. She searched for neurological evaluation, and her neurological exam showed signs of cerebellar impairment (loss of balance, dysmetria and dysdiadochokinesia) mainly in the right arm associated with bilateral papilledema. We performed a magnetic resonance (MRI) of the brain, which showed a tumoral lesion with expansive characteristics in the posterior fossa enhanced after gadolinium infusion (►Fig. 1). We indicated surgical procedure to remove the tumor (►Fig. 2), and controlled post-operative intracranial pressure with a monitoring catheter placed in the left cerebral ventricle.

The tumor size was 5 × 4 cm and located in the cerebellar vermis. Macroscopically, it had a light gray color, with a friable texture, and a bleeding infiltrating pattern, involving local venous drainage. Anatomopathological analysis diagnosed the tumor as undifferentiated large cell carcinoma, consistent with metastases from urothelial bladder carcinoma/transitional cell carcinoma (►Fig. 3). During the post-operative period, the patient developed intracranial hypertension. We performed a ventricle-peritoneal bypass 10 days after primary surgery. After this second procedure, the patient recovered neurological and clinical status, receiving hospital discharge. We performed patient follow-up for 20 months, when the patient died from systemic complications of extra cranial tumor return.
Discussion

Distant TCC metastases are related to the depth of penetration by the tumor into the muscular wall, and the most common sites of metastatic spread are regional lymph nodes, lung, and bones.3,4 Other common metastasis sites include liver, adrenal gland, and intestine.5,6 Intracranial metastasis in this context was first described by Lower and Watkins in 1924,7 and, although it remains an infrequent clinical manifestation, the number of central nervous system lesions from bladder cancer has increased since 1980.8

When the CNS is involved, it frequently occurs as a late event in the course of bladder carcinoma, such as a patient with advanced stage of disease. The improvement in chemotherapy alone or associated with radiological techniques for treatment in the primary organ may have prolonged the survival expectancy for these patients. As such, the higher survival rates increase the risk of developing uncommon metastatic lesions, such as brain and lepto-meningeal metastases.

According to current medical literature, the incidence of CNS evolvement of disseminated TCC varies from 0.6% - 8%9–11 and bladder carcinoma accounts for 0.5% of all intracranial metastases.9 Brain metastases as the first metastatic manifestation without evidence of recurrent or disseminated disease is extremely rare, with only few cases reported in the literature.8–10 These lesions may be solitary or multiple, and may involve either the cerebral hemispheres or the cerebellum.12 Sarmiento et al13 states that metastasis to the frontal lobe seems to be the most common location of single lesions, followed by the temporal and parietal lobes. Moreover, cerebellar isolated involvement has been described in only four patients.12,13

Meningeal carcinomatosis (MC) is a rare involvement of solid tumors, particularly seen in breast and lung cancer. There are only a few cases that describe MC secondary to TCC. A study performed by Anderson et al in 2003 analyzed a total of 359 patients with bladder cancer and found an incidence of 1% of brain metastasis; no patient developed MC. Two different articles published in 2010 and 2011 found, respectively, 22 and 30 cases of MC secondary to TCC.14,15

Some studies suggest that the incidence of central nervous system metastases is higher in patients who received aggressive initial treatment for bladder carcinoma.16,17 Before chemotherapy, metastases to the central nervous system occurred in less than 1% of patients.6 Supported by the fact that in the last decades the number of chemotherapeutic options increased as well as its effectiveness, a systemic control of the disease is frequently achieved. Moreover, better local control of the tumor with surgeries, associated or not with radiation therapy, extends the natural history of the disease, and consequently the number of late metastasis increases, such as intracranial lesions.18,19

A possible explanation for such a phenomenon is that the CNS may act as a sanctuary for residual tumor due to poor penetration of the chemotherapeutic agents through the blood-brain barrier. Thus, with better control of systemic disease and improved survival, CNS metastases as a late complication may become more common.11,12,17,20

This theory is advocated by many authors who believe that aggressive chemotherapy (in a regimen including methotrexate, vinblastine, doxorubicin, and cisplatin) prolongs the duration of tumor remission but does not cross the blood-brain barrier.4,11,20 In other words, the advent of the new chemotherapy regimen improved the primary and systemic control of the urinary bladder cancer, allowing patients to live long enough to develop cerebral metastasis.13

According to Rabadán et al, the median time between TCC diagnosis and its metastasis is 12 to 18 months, and usually the patient has multiple organs involved, not only the CNS.21 Our patient, on the other hand, was diagnosed with cerebellar lesion, and did not have any radiologic sign or clinical symptom of systemic relapse. It has been suggested that abdominal and pelvic neoplasms may have a propensity for metastasis to the cerebellum, possibly as a result of retrograde dissemination through the vertebral venous system via Batson’s plexus, bypassing the liver and lung, terminating in the intracranial venous sinuses at the foramen magnum. Such a mechanism may explain the finding of cerebellar metastasis, despite the absence of other systemic metastases.19,22

CNS metastases involve cerebral hemispheres in 80% of the cases, 5% in the brainstem and 15% in the cerebellum.11 According to tumor localization, the patient may complain of regular and unspecific headache, or suddenly develop seizures, neurologic deficit, or behavioral changes.21 Patients with cerebellar metastases often complain about occipital and/or frontal headaches and gait disturbances.22

Treatment of intracranial metastasis from TCC is not a simple and standardized procedure. From a general point of view, surgical excision followed by brain radiotherapy has been considered the mainstay treatment for brain metastases.4,5 However, therapeutic decision varies with the site and number of brain metastasis, and also with the systemic disease’s control.

In the absence of other systemic metastases (extra cranial disease is controlled), patients with solitary CNS metastases from bladder carcinoma and good prognosis may benefit from surgical resection,12 followed, or not, by whole brain radiation therapy. If the patient has a solitary lesion, no bigger than 30 mm, a therapeutic option is stereotactic radiosurgery, of which the results are comparable to regular surgery.17

External beam cranial irradiation may be a beneficial form of therapy in multiple brain metastasis and may offer effective palliation for patients with progressive systemic disease or multiple CNS metastases.12,17 It is important to emphasize that, historically, chemotherapy has not been an option for intracranial metastasis, given that most anti-tumor drugs do not cross the brain-blood barrier.8,17 However, Albers et al and Protzel et al reported good results of intracranial single or multiple metastases, treated with gemcitabine alone or associated with whole brain radiation.4,23 Gemcitabine is a small molecular size and low protein binding drug that appears to cross the blood-brain barrier.4 Therefore, these
authors conclude that gemcitabine is a new chemotherapeutic option for palliative treatment of advanced TCC, especially in patients with poor performance status whose therapy goal is primarily palliative.

Brain metastases from TCC represent a serious and debilitating complication and survival is brief after diagnosis. The life expectancy after diagnosis varies from 2 to 14 months, but most patients survive less than 6 months. However, long-term survival greater than 1 to 2 years is observed in up to 10% of patients with favorable prognostic factors, such as a solitary lesion, good Karnofsky performance status, and absent extra cranial disease. The patient herein described had a survival follow-up of 20 months, and died from systemic oncologic complications, with no signs of CNS tumor return. Therefore, a complete systemic investigation and metastasis resection, when possible, is indicated given that this treatment prolongs survival rates in this scenario.

Conclusion

Authors report a case of a patient with late metastasis from transitional cell carcinoma that underwent optimized oncologic therapy of the primary tumor. According to medical literature, the incidence of brain lesions secondary to bladder cancer has increased in the last few decades. However, no reports had been described in Brazilian literature, which makes this case unique in our country.

References